Do broadly neutralising antibodies really have a future in treating HIV?
Who is at risk of injectable treatment failure?
‘Real world’ injectable treatment halves patient dissatisfaction, with only two viral failures in first six months
Survival prospects for older people with HIV plotted accurately by simple scoring system
After viral rebound, dolutegravir-based treatment more likely to suppress HIV
CD4 and white blood cell declines caused by islatravir are dose-related and reversible, but rule out using it for prevention
Low-level HIV and viral load blips are important warning signals, European study finds
The paediatric drug pipeline should include improvements to current HIV treatment, long-acting formulations and antibodies
Dolutegravir has direct effects on fat cells
